Dr Reddys Laboratories Ltd
DRREDDYBSE 500124PharmaceuticalsMkt cap ₹1,00,165 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹8,100 Cr
YoY -5.5%QoQ +7.3%
Net profit · Q1 FY27
₹436 Cr
YoY -69.1%QoQ +96.8%
Net margin · Q1 FY27
5.4%
-11.1 pts vs Q1 FY26
Net profit · FY26
₹4,158 Cr
YoY -27.4%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 8,100 | 7,546 | 8,753 | 8,828 | 8,572 | -5.5% |
| Other income | 355 | 475 | 269 | 324 | 290 | +22.2% |
| Total income | 8,455 | 8,022 | 9,022 | 9,152 | 8,862 | -4.6% |
| Profit before tax | 553 | 195 | 1,541 | 1,739 | 1,905 | -71.0% |
| Tax | 118 | -21.60 | 354 | 408 | 495 | -76.2% |
| Net profit | 436 | 221 | 1,190 | 1,337 | 1,410 | -69.1% |
| Net margin | 5.4% | 2.9% | 13.6% | 15.1% | 16.4% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 33,700 | 32,644 | 28,011 | 24,670 | 21,545 | +3.2% |
| Other income | 1,358 | 1,097 | 894 | 1,056 | 484 | +23.8% |
| Total income | 35,059 | 33,741 | 28,905 | 25,725 | 22,030 | +3.9% |
| Profit before tax | 5,379 | 7,658 | 7,186 | 6,012 | 2,991 | -29.8% |
| Tax | 1,235 | 1,954 | 1,623 | 1,541 | 879 | -36.8% |
| Net profit | 4,158 | 5,725 | 5,578 | 4,507 | 2,183 | -27.4% |
| Net margin | 12.3% | 17.5% | 19.9% | 18.3% | 10.1% |
BIC's take
We haven't covered Dr Reddys Laboratories Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:54 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.